Breaking news

WHO’s Historic Agreement: A Major Step Towards Global Pandemic Preparedness

In a groundbreaking move, members of the World Health Organization (WHO) have reached a historic, legally binding agreement aimed at preparing the world for future pandemics. This pact, designed to address the lessons learned from the COVID-19 crisis, sets the stage for a more equitable global response to health emergencies, particularly in the distribution of essential drugs, vaccines, and medical technologies.

The agreement marks a significant milestone in global health governance, especially at a time when multilateral institutions like the WHO are facing considerable financial strain. The United States, which was once the WHO’s largest financial contributor, withdrew from negotiations after President Donald Trump initiated the U.S.’s departure from the organization. Despite this setback, the deal underscores a strong commitment from member states to work together on global health security, with or without U.S. involvement. “This is a historic moment,” said Nina Schwalbe, founder of global health think tank Spark Street Advisors. “It demonstrates that countries are committed to multilateralism and to collective action.”

This agreement, the second of its kind in WHO’s 75-year history (the first being a tobacco control treaty in 2003), focuses on structural inequalities in how pandemic-related health tools are developed and distributed. Article nine of the deal ensures that future pandemic-related drugs, therapeutics, and vaccines will be made globally accessible. It also gives the WHO stronger oversight over medical supply chains and paves the way for local production of vaccines during health crises.

A key challenge in the negotiations was the issue of technology transfer—sharing the knowledge and manufacturing capabilities necessary for lower-income countries to produce their vaccines and treatments. To address this, the agreement mandates that manufacturers allocate at least 20% of their real-time production to the WHO during a pandemic, with a minimum of 10% designated for donation and the rest priced affordably for developing nations.

The deal is not yet finalized, as it must be adopted at the WHO Assembly in May, and some details, such as the annex on Pathogen Access and Benefit Sharing, still require further negotiation. However, once ratified, the agreement will bolster global preparedness, enabling quicker responses to future pandemics and more equitable access to life-saving resources.

As health experts emphasize, the global community must invest in preparedness now to avoid the costly toll of another pandemic. “We can’t afford another pandemic, but we can afford to prevent one,” said Helen Clark, co-chair of The Independent Panel for Pandemic Preparedness. This agreement represents a critical step toward ensuring that the world is better equipped to face future health crises with solidarity, transparency, and a commitment to equity.

Mitsides Lifts First-Half Profit 14% As Margin Gains Offset Softer Sales

Mitsides Public Company Ltd posted a solid improvement in first-half profitability in 2026, with net profit rising almost 14 per cent despite a modest decline in revenue, supported by a stronger gross margin and lower financing costs.

According to the group’s interim financial statements, published on its website (Mitsides Group), profit after tax increased to €727,134 in the six months to June 30, from €640,011 a year earlier, an advance of 13.6 per cent.

Margins and Finance Costs Drive The Improvement

Turnover edged down 1.05 per cent to €18.92 million, compared with €19.12 million in the corresponding period of 2025. Mitsides, which produces and distributes flour and pasta, imports and distributes food products, trades grain and operates in Serbia through its wholly owned subsidiary Mitsides Point, nonetheless delivered stronger profitability across key lines.

The main driver was a wider gross margin, which increased to 27.96 per cent from 26.7 per cent a year earlier. Operating profit also improved, rising to €1.07 million from €1.03 million in the first half of 2025.

At the same time, selling, promotion and administrative expenses increased to €4.21 million, or 22.25 per cent of sales, from €4.03 million, or 21.08 per cent of sales, a year earlier. Even with that rise in overheads, the group benefited from lower borrowing costs, helping preserve momentum at the bottom line.

Lower Borrowing Costs Support Earnings

Net finance expenses fell 25 per cent to €163,225 from €217,775. As a result, profit before tax climbed to €902,192 from €810,508 in the comparable period of 2025. Earnings per share rose to 8.87 cents from 7.81 cents.

The company also reported an improvement in short-term liquidity. Its current ratio increased to 1.35 at the end of June from 1.25 at the end of 2025, although the quick ratio softened to 0.63 from 0.69.

Balance Sheet Strength Improves

Total assets stood at €38.01 million, down from €40.01 million at the end of December, while shareholders’ equity increased to €19.95 million from €19.23 million. Net asset value per share rose to €2.43 from €2.35.

At June 30, the group had €6.94 million in floating-rate borrowings, trade receivables of €7.75 million and bank balances of €717,088.

Growth Plans Continue Amid Geopolitical Uncertainty

Looking ahead, Mitsides said it will continue investing to expand exports while defending its position in the Cypriot market. The group also highlighted uncertainty linked to the wars in Ukraine and the Middle East, as well as persistent inflationary pressures.

In Serbia, where operations are carried out through the wholly owned subsidiary Mitsides Point D.o.o., the business continued to operate against a backdrop of political and economic uncertainty. The company noted that Serbia remains committed to its European path, with the government aiming to complete the technical criteria for EU accession by the end of 2026.

The board did not recommend an interim dividend for the period. Separately, Mitsides completed payment in August of a €410,000 final dividend, equivalent to €0.05 per share, drawn from profits accumulated during the 2023 financial year.

Uol
eCredo
The Future Forbes Realty Global Properties
Aretilaw firm

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter